Early investigational drugs targeting tau protein for the treatment of Alzheimer's disease - Wikidata - wikimedia - TriplyDB

Early investigational drugs targeting tau protein for the treatment of Alzheimer's disease

Early investigational drugs targeting tau protein for the treatment of Alzheimer's disease

http://www.wikidata.org/entity/Q33887379

about

Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease Natural Antibodies as Rheostats for Susceptibility to Chronic Diseases in the Aged The relationship between complement factor C3, APOE ε4, amyloid and tau in Alzheimer's disease Tau passive immunization inhibits not only tau but also Aβ pathology Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium.Physiological and Pathophysiological Implications of Synaptic Tau.Pyrrolo[2,3-c]pyridines as Imaging Agents for Neurofibrilary Tangles.Tau aggregation inhibitors: the future of Alzheimer's pharmacotherapy?Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy.X-Ray Structural Study of Amyloid-Like Fibrils of Tau Peptides Bound to Small-Molecule Ligands.

P2860

Q26739412-03363DE1-36A5-49C6-A0BE-3294ABFFB566 Q26752508-DED141AC-7F04-4028-BE13-5530BB5C5227 Q37054759-E8F4D231-3042-42BC-87E5-9F4A397B9EA8 Q37579019-9BCF3FA3-C23D-422E-9BA4-2A611990D24A Q38715233-6B817F10-6E62-479C-ACAC-985B0F08F00E Q38747530-9B72380E-A854-42D8-9D8A-35EDC9E38EFC Q41789603-707F99E8-7356-48BA-83D7-9BFF55148353 Q48239696-A85C70CF-0C54-4B8B-A891-A0438D44FAA9 Q50632272-9E451BC5-3DF1-4030-8FAF-254AE676407E Q51263493-82D5DC31-79AB-4D1D-A2D3-46CB06090587

P2860

Early investigational drugs targeting tau protein for the treatment of Alzheimer's disease

http://www.wikidata.org/entity/Q33887379

description

2015 nî lūn-bûn

@nan

2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Early investigational drugs ta ...... eatment of Alzheimer's disease

@ast

Early investigational drugs ta ...... eatment of Alzheimer's disease

@en

type

label

Early investigational drugs ta ...... eatment of Alzheimer's disease

@ast

Early investigational drugs ta ...... eatment of Alzheimer's disease

@en

prefLabel

Early investigational drugs ta ...... eatment of Alzheimer's disease

@ast

Early investigational drugs ta ...... eatment of Alzheimer's disease

@en

P1433

Q33887379-D309EFC8-AA47-42CF-BC06-B084C6FBE256

P1476

Q33887379-D2CF8108-E370-4142-8607-87968F369439

P2093

Q33887379-08086A79-DB30-413A-BE62-67A15199FEC6

Q33887379-EDC552FE-714B-4F52-BD08-A1721773B195

P2860

Q33887379-011EB383-7485-4FAA-8D6C-9E4B296A0DC0

Q33887379-0487E34A-D011-4323-AE82-0290A3E39ED1

Q33887379-31023C05-2F5E-463E-B448-6FF8BF887359

Q33887379-36FA7519-68B9-4E89-AD06-5D503AEE32B4

Q33887379-3C11BE34-3A40-4EF6-B63E-AB35908FDDE7

Q33887379-3DEB24F7-4213-4DBC-8508-EEE38D7D912B

Q33887379-3E61E59B-166B-4453-9C46-BCF23EA78C0C

Q33887379-4B0B8D79-45B6-4676-8093-509EA5BD19E8

Q33887379-4D24724C-0F26-4C9A-81EC-6F9ADF091703

Q33887379-5C431702-4AC7-42F2-A1B5-0A941F8DCC58

P304

Q33887379-442EBB95-F9F6-46B1-8512-B9CDFEB06E1C

P31

Q33887379-CD3E6409-4534-45E3-8B88-84D12C2F3442

P356

Q33887379-02E373EE-6C9D-4958-85CC-B315169B855E

P407

Q33887379-C466C4C9-AF65-4D8D-AF6C-C0524290FCDB

P433

Q33887379-ACF26D84-DA75-4F00-B6EB-93CF222D47BC

P478

Q33887379-EA6874AB-EA60-444D-8CAE-900AE2112841

P577

Q33887379-4D1A6447-00EA-4F03-AC94-3320FAE5780A

P698

Q33887379-871BAFC6-3903-4857-8C69-6F33BA85C1FC

P932

Q33887379-732A2FEF-0A94-4E34-8908-44470D1B54FB

P356

13543784.2015.1075002

P1433

Expert Opinion on Investigational Drugs

P1476

Early investigational drugs ta ...... eatment of Alzheimer's disease

@en

P2093

Keshav Anand

http://www.w3.org/2001/XMLSchema#string

Marwan Sabbagh

http://www.w3.org/2001/XMLSchema#string

P2860

Alzheimer's Disease

Tau-aggregation inhibitor therapy for Alzheimer's disease

Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau

Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology

Chronic divalproex sodium use and brain atrophy in Alzheimer disease

Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders

Long-term lithium treatment reduces glucose metabolism in the cerebellum and hippocampus of nondemented older adults: an [¹⁸F]FDG-PET study

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

A phase II trial of tideglusib in Alzheimer's disease.

Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy.

P304

1355-1360

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2015.1075002

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26289787

http://www.w3.org/2001/XMLSchema#string

P932

5502785

http://www.w3.org/2001/XMLSchema#string